Our clinical data in SCLC confirms what others have consistently shown in pre-clinical models and a small number of clinical studies, that there is an association between low SLFN11 tumour expression and resistance to directly DNA-damaging therapies, particularly in this indication [3–7, 11, 17, 30, 31]. The gene discussed is SLFN11; the disease is neoplasm.